07/02/2018
EQS-News

Zur Rose Group AG: Statement on the draft coalition agreement in Germany: Rx mail-order ban not to be justified

EQS Group-News: Zur Rose Group AG / Key word(s): Statement

07.02.2018 / 17:49


Press release

Statement on the draft coalition agreement in Germany: Rx mail-order ban not to be justified

As per the draft coalition agreement of the parties CDU/CSU and SPD published today the parties intend to implement a ban on mail-order of prescription drugs in order to strengthen local pharmacies. Based on expert opinions and statements of previous federal governments, the Zur Rose Group remains convinced that this intention is unconstitutional and incompatible with European law. The company is therefore very surprised that these assessments were apparently not sufficiently considered and that this intention was included in the draft coalition agreement. In the interest of patients the Zur Rose Group will therefore take all necessary legal and operative steps both in Germany and at European level.

Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail: ir@zurrose.com, telephone: +41 52 724 00 64

Media contact
Lisa Lüthi, Head of Corporate Communications
e-mail: lisa.luethi@zurrose.com, telephone: +41 52 724 08 14

Zur Rose Group

Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose Group is Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical doctors. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care. while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders.

The Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. Customers in Germany and Austria are primarily supplied from Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 1000 people at its various locations, Zur Rose Group generated revenue of CHF 983 million in 2017. Zur Rose Group AG's shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX Swiss Exchange. More information at zurrosegroup.com.



End of Corporate News



show this
Media Release (PDF)
Zur Rose Group
06/04/2022
Ad hoc News

Zur Rose Group AG publishes invitation to the Annual General Meeting of 28 April 2022

Read more
Max Müller to
28/03/2022
Corporate News

Max Müller to be new CEO of TeleClinic, taking over from founder and former CEO Katharina Jünger

Read more
Zur Rose Group:
24/03/2022
Ad hoc News

Zur Rose Group: Excellent starting position for e-prescriptions set up and ecosystem strategy successfully continued

Read more
Zur Rose Group:
20/01/2022
Corporate News

Zur Rose Group: steady growth in a volatile market environment

Read more
Zur Rose Group
10/01/2022
Corporate News

Zur Rose Group nominates Rongrong Hu as director

Read more
Zur Rose and
16/12/2021
Corporate News

Zur Rose and the Swiss Association for the Blind and Visually Impaired make it easier for people with a visual impairment to take medication

Read more
01/06